Literature DB >> 2457075

Antibodies against arylcyclohexylamines and their similarities in binding specificity with the phencyclidine receptor.

S M Owens1, M Zorbas, D L Lattin, M Gunnell, M Polk.   

Abstract

Rabbit antibodies were generated against five unique epitopes of phencyclidine (PCP)-like molecules to determine the molecular requirements for arylcyclohexylamine binding to the PCP receptor. Three of the haptens contained the three ring structures of PCP. A fourth hapten was synthesized from a derivative of the highly potent PCP analog, 1-[1-(2-thienyl)cyclohexyl]piperidine. The fifth hapten, 5-[N-(1'-phenylcyclohexyl)amino]pentanoic acid, was used as a haptenic model for N-ethyl-1-phenylcyclohexylamine, one of the most potent arylcyclohexylamines. These haptens were bound covalently to bovine serum albumin and were then used as antigens to immunize rabbits. The affinities and cross-reactivity patterns of the resulting five antibodies were studied in a [3H]PCP radioimmunoassay using standard curves of various arylcyclohexylamines. The dissociation constants ranged from 1.9 to 51.6 nM. From the average IC50 values of the radioimmunoassay dose-response curves, the relative potency of each ligand to PCP was determined. Least-squares linear regression was used to correlate these data with relative potency data from two [3H]PCP receptor binding assays and a PCP drug discrimination assay in the rat. Only relative potency data from the anti-5[N-(1'-phenylcyclohexyl)amino]pentanoic acid antibody showed a significant correlation with data from the three pharmacological studies (r2 = 0.80, 0.57 and 0.78, respectively; p less than .05 in all cases). These data indicated the 5-[N-(1'-phenylcyclohexyl)amino]pentanoic acid hapten contained the pharmacologically active features needed for arylcyclohexylamine binding to the PCP receptor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2457075

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse.

Authors:  F Ivy Carroll; Philip Abraham; Paul K Gong; Ramakrishna R Pidaparthi; Bruce E Blough; Yingni Che; Amber Hampton; Melinda Gunnell; Jackson O Lay; Eric C Peterson; S Michael Owens
Journal:  J Med Chem       Date:  2009-11-26       Impact factor: 7.446

2.  Synthesis of mercapto-(+)-methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines.

Authors:  F Ivy Carroll; Bruce E Blough; Ramakrishna R Pidaparthi; Philip Abraham; Paul K Gong; Liu Deng; Xiaodong Huang; Melinda Gunnell; Jackson O Lay; Eric C Peterson; S Michael Owens
Journal:  J Med Chem       Date:  2011-06-29       Impact factor: 7.446

3.  Impact of distinct chemical structures for the development of a methamphetamine vaccine.

Authors:  Amira Y Moreno; Alexander V Mayorov; Kim D Janda
Journal:  J Am Chem Soc       Date:  2011-04-07       Impact factor: 15.419

4.  The Development and Characterization of an scFv-Fc Fusion-Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse.

Authors:  Charles E Hay; Laura E Ewing; Michael D Hambuchen; Shannon M Zintner; Juliana C Small; Chris T Bolden; William E Fantegrossi; Paris Margaritis; S Michael Owens; Eric C Peterson
Journal:  J Pharmacol Exp Ther       Date:  2020-04-03       Impact factor: 4.030

5.  Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody.

Authors:  H Marie Lacy; Melinda G Gunnell; Elizabeth M Laurenzana; S Michael Owens
Journal:  Int Immunopharmacol       Date:  2007-10-23       Impact factor: 4.932

6.  Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine.

Authors:  Eric C Peterson; Elizabeth M Laurenzana; William T Atchley; Howard P Hendrickson; S Michael Owens
Journal:  J Pharmacol Exp Ther       Date:  2008-01-11       Impact factor: 4.030

7.  Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats.

Authors:  Elizabeth M Laurenzana; Howard P Hendrickson; Dylan Carpenter; Eric C Peterson; W Brooks Gentry; Michael West; Yingni Che; F Ivy Carroll; S Michael Owens
Journal:  Vaccine       Date:  2009-10-01       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.